GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLMW) » Definitions » Total Tax Payable

Apollomics (Apollomics) Total Tax Payable : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Total Tax Payable?

Apollomics's Total Tax Payable for the quarter that ended in Dec. 2023 was $0.00 Mil.


Apollomics Total Tax Payable Historical Data

The historical data trend for Apollomics's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Total Tax Payable Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Tax Payable
0.15 - - -

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Tax Payable Get a 7-Day Free Trial - - - - -

Apollomics Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.


Apollomics Total Tax Payable Related Terms

Thank you for viewing the detailed overview of Apollomics's Total Tax Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollomics (Apollomics) Business Description

Traded in Other Exchanges
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.